Phaseline

Companies › Changchun Intellicrown Pharmaceutical

Changchun Intellicrown Pharmaceutical: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology, Gastroenterology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IMM-H014–Phase 1Nonalcoholic Steatohepatitis (NASH)–
ZZ06
EGFR-targeting biologic (mechanism unclear)
–Phase 1Advanced EGFR Positive Solid Tumor–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06216041IMM-H014Phase 1Nonalcoholic Steatohepatitis (NASH)GastroenterologyJun 2025
NCT04412616ZZ06Phase 1Advanced EGFR Positive Solid TumorOncologyDec 2025

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.